2613MO Identifying biomarkers of response to first-line nivolumab plus ipilimumab therapy in patients with metastatic clear cell renal cell carcinoma (mccRCC) enrolled in the COSMIC 313 trial.
Saved in:
| Title: | 2613MO Identifying biomarkers of response to first-line nivolumab plus ipilimumab therapy in patients with metastatic clear cell renal cell carcinoma (mccRCC) enrolled in the COSMIC 313 trial. |
|---|---|
| Authors: | Simsek, B.1 (AUTHOR), Niman, S.M.2 (AUTHOR), El Ahmar, N.1 (AUTHOR), Mohanna, R.A.1 (AUTHOR), Delcea, A.1 (AUTHOR), De Oliveira, G.R.1 (AUTHOR), Laimon, Y.N.1 (AUTHOR), Ascione, L.3 (AUTHOR), Xie, W.4 (AUTHOR), Braun, D.A.5 (AUTHOR), Sun, M.3 (AUTHOR), Saad, E.3 (AUTHOR), El Masri, J.3 (AUTHOR), Freeman, G.J.3 (AUTHOR), Simmons, A.6 (AUTHOR), Aftab, D.7 (AUTHOR), Motzer, R.J.8 (AUTHOR), Atkins, M.B.9 (AUTHOR), Choueiri, T.K.10 (AUTHOR), Signoretti, S.1 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1402-S1403. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
